Acarbose (Glucobay, BAYG5421)
Sponsors
Bayer
Conditions
Diabetes MellitusDiabetes Mellitus, Type 2Diabetes Mellitus, Type II
Phase 1
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
CompletedNCT01388153
Start: 2011-06-30End: 2011-08-31Updated: 2013-08-28
A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg
CompletedNCT01554631
Start: 2012-03-31End: 2012-05-31Updated: 2013-06-14
Bioequivalence Study for Acarbose / Metformin FDC
CompletedNCT01728740
Start: 2012-09-30End: 2012-12-31Updated: 2012-12-19
Phase 3
Phase 4
Unknown Phase
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
CompletedNCT00909051
Start: 2009-03-24End: 2010-12-31Updated: 2023-06-06
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
CompletedNCT01167231
Start: 2007-05-31End: 2008-06-30Updated: 2010-08-25
GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin
CompletedNCT01248481
Start: 2010-09-30End: 2012-07-31Updated: 2013-06-20